How much do you have to reduce Lp(a) to achieve significant clinical benefit?
Bempedoic acid: The new kid on the block
Immunotherapies in homozygous FH: Alirocumab and evinacumab
Remnant lipoproteins and impact of PCSK9 inhibition
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
Genetic risk scores: How much do they add?
Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial
Lp(a): Findings in ODYSSEY OUTCOMES
What’s new in very high-risk patients?
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
Lp(a): Risk factor or causal factor? A critical appraisal
ODYSSEY OUTCOMES and stroke events
Treat ischaemic stroke to target
Endothelial LDL transcytosis in atherosclerosis
Emerging lipid science: ApoE and chronic disease
ODYSSEY OUTCOMES: Update
New data from FOURIER and design of the VESALIUS-CV Trial
PCSK9 Genetics: New Insights
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins